Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27722980 | 0.91 | RAB9A (0.32) | RAB9ANPC1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL31121574 | 0.88 | NPC1 (0.30) | RAB9ANPC1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL28757379 | 0.88 | NPC1 (0.30) | RAB9ANPC1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL8526230 | 0.80 | FFAR1 (0.32) | RAB9ACYP1A2SMN1; SMN2 | |
| SCHEMBL28788996 | 0.79 | PDK2 (0.38) | — | |
| SCHEMBL2121108 | 0.78 | SRR (0.32) | — | |
| SCHEMBL5014699 | 0.77 | MAPT (0.31) | SMN1; SMN2MAPT | |
| SCHEMBL3947332 | 0.76 | THRB (0.31) | — | |
| SCHEMBL27633572 | 0.76 | PDK2 (0.33) | RAB9ANPC1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL316146 | 0.76 | THRB (0.32) | CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101068773-A | Melanin concentrating hormone antagonists | PROCTER & GAMBLE (US) | 2007-11-07 | — | — | CN | claimed |
| CN-115160098-B | Oxygen-containing compound deoxidization methylation method | 中国科学院兰州化学物理研究所 | 2023-06-06 | — | — | CN | disclosed |
| CN-115160098-A | Oxygen-containing compound deoxidation and methylation method | 中国科学院兰州化学物理研究所 | 2022-10-11 | — | — | CN | disclosed |
| CN-104987326-B | The set of reactive mass labels | 电泳有限公司 | 2019-08-30 | — | — | CN | disclosed |
| CN-105451737-B | Medical composition and its use and described pharmaceutical composition are used for the application process practised contraception on demand | 拜耳医药股份有限公司 | 2018-04-10 | — | — | CN | disclosed |
| CN-101313223-B | Mass labels for biomolecules comprising a 2, 6-dimethyl-piperidin-1-yl-methylene or pyrimidin-2-ylthiomethylene mass label moiety and a succinimidyl-oxy-carbonyl active functional group | 电泳有限公司 | 2017-04-12 | — | — | CN | disclosed |
| CN-104987326-A | Mass labels for biomolecules containing a 2,6-dimethyl-piperidin-L-YL methylene or a pyrimidin-2-YL thiomethylene mass marker moiety and a succinimid-oxy-carbonyl reactive functional group | ELECTROPHORETICS LTD | 2015-10-21 | — | — | CN | disclosed |
| CN-1960969-B | Histamine H3 receptor agents, methods of preparation and therapeutic uses thereof | LILLY CO ELI | 2012-03-28 | — | — | CN | disclosed |
| CN-101119974-A | Amide derivatives as PPAR activators | HOFFMANN LA ROCHE (CH) | 2008-02-06 | — | — | CN | disclosed |
| CN-101068773-A | Melanin concentrating hormone antagonists | PROCTER & GAMBLE (US) | 2007-11-07 | — | — | CN | disclosed |
| CN-1960969-A | Histamine H3 receptor agents, methods of preparation and therapeutic uses thereof | LILLY CO ELI (US) | 2007-05-09 | — | — | CN | disclosed |
| CN-1832920-A | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA INC (US) | 2006-09-13 | — | — | CN | disclosed |
| CN-1703395-A | Aryl and heteroaryl compounds and methods of modulating blood coagulation | TRANSTECH PHARMA INC (US) | 2005-11-30 | — | — | CN | disclosed |
| CN-1556788-A | Muscarinic agonists | — | 2004-12-22 | — | — | CN | disclosed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| CN-1280561-A | Amidocarboxylic acid derivatives | SANKYO CO (JP) | 2001-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | RAB9A 2511/4885NPC1 18/4885CYP1A2 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.